



Enzymatica
THE SCIENCE THAT PROTECTS

Interim Report Q3/2026

January–September 2026

Enzymatica AB develops health products based on Penzyme® technology, which contains marine enzymes. The main product is ColdZyme® – a mouth spray for colds and cold-like symptoms in the upper respiratory tract. The Group's strategy is to grow by strengthening its position in existing markets and expanding internationally through established partners. Enzymatica is headquartered in Lund and is listed on Nasdaq First North Growth Market. Certified Adviser is DNB Carnegie Investment Bank AB (publ). For more information please visit www.enzymatica.se.

Enzymatica AB (publ)

Interim Report January–September 2026

Q3	January-September
- Net sales reached SEK 14.6 (15.0) million. - The operating result totaled SEK -3.9 (-8.2) million. - Earnings per share, basic and diluted, were SEK -0.02 (-0.03). - Cash flow from operating activities totaled SEK -5.8 (-12.2) million.	- Net sales reached SEK 33.2 (35.6) million. - The operating result totaled SEK -30.1 (-41.1) million. - Earnings per share, basic and diluted, were SEK -0.13 (-0.17). - Cash flow from operating activities for the period totaled SEK -24.3 (-41.4) million.

Key figures

(SEK million)	Q3 2026	Q3 2025	Jan–Sep 2026	Jan–Sep 2025	Full year 2025
Net sales	14.6	15.0	33.2	35.6	53.9
Gross margin, %	65	62	58	62	61
Operating profit/loss	-3.9	-8.2	-30.1	-41.1	-51.4
Cash flow from operating activities	-5.8	-12.2	-24.3	-41.4	-41.0
Net debt/Net cash			6.7	31.8	32.1
Average number of employees	14	21	17	21	21

“With our first deliveries to STADA and a new partnership in the MENA region, we are turning our international expansion plans into action.”

Sana Alajmovic



Enzymatica AB (publ)

Interim Report January–September 2026

Significant events during the quarter	Significant events after the quarter
No significant events occurred during the quarter.	- On October 21, 2026, Enzymatica announced a partnership agreement with MMDS-backed MedonyX for the registration, marketing, sale and distribution of ColdZyme in Jordan and Iraq. The company expects to launch ColdZyme in both markets in the first quarter of 2027, following regulatory approval. - An extraordinary general meeting was held on October 22. The meeting resolved to implement a long-term incentive program for 2026/2029 for the company's management and key personnel, comprising up to 1,000,000 warrants with a subscription period during the fourth quarter of 2029. - On October 27, it was announced that Guðmundur Pálmason had decided to step down from Enzymatica's Board of Directors for personal reasons. Guðmundur Pálmason had served on the company's Board since 2016.
Other events during and after the quarter	
- On October 28, it was announced that Truls Möregårdh is investing in Enzymatica and becoming a brand ambassador for ColdZyme. - On October 20, 2026, Enzymatica AB entered into a three-year loan agreement with Almi for SEK 10 million. See "Financing and cash flow" on page 7. - On October 1, 2026, Enzymatica AB entered into a three-year loan facility totaling SEK 3 million. See "Related-party transactions" on page 8. - On August 27, Enzymatica announced that both a Nordic Marketing and Sales Director and a Chief Scientist and Head of Production had joined the Group Management Team.	



CEO Sana Alajmovic:

ColdZyme enters new markets



ColdZyme continued to strengthen its position in the Swedish pharmacy market during the third quarter. Consumer sales grew faster than the cold category, and the market share increased. At the same time, our continued cost control contributed to improved earnings and cash flow. In addition, the agreement with MedonyX marked another concrete step in our international expansion.

Stronger position in our home market

Net sales reached SEK 14.6 (15.0) million. One important reason for the decline is that the comparison period included the launch of our eucalyptus variant in fall 2025. The pharmacies' initial stocking temporarily boosted sales to pharmacies in September. Inventory adjustments at Swedish pharmacies also affected sales. At the same time, the positive trend in the UK continued, with sales increasing by 51 percent to SEK 1.7 million.

During the quarter, ColdZyme's consumer sales¹ in Sweden increased by 10.6 percent in value, compared with growth of 6.7 percent in the cold category. Market share rose to 6.5 percent from 6.2 percent. During the first nine months of the year, consumer sales increased by 4.9 percent, while the category as a whole remained largely unchanged.

1) IQVIA Total Pharmacy, Value, September 2026

Pharmacies remain our most important channel in the Swedish market. We have deepened our collaboration with both physical and online pharmacies through training, advice and joint marketing activities. At the same time, we have begun work to expand distribution to grocery and convenience stores. Our aim is to complement the pharmacy channel step by step and make ColdZyme available in more relevant purchasing situations.

Through our long-term ambassador partnership with Truls Möregårdh, a table tennis player who won two Olympic silver medals at Paris 2024 and a singles silver medal at the 2021 World Championships, we are bolstering our consumer communication and building a clearer connection between ColdZyme, performance and an active lifestyle. The partnership also creates content and visibility for the Swedish market and our international partners.

International expansion with concrete milestones

After the quarter ended, we made the first deliveries to STADA for Germany. Following extensive preparations, this marks an important milestone as the partnership moves toward a commercial launch this fall.

We have also signed a distribution agreement with MMDS for Jordan and Iraq, where the product will launch under the ColdZyme brand. The agreement is our first concrete step into the MENA region, where we see potential in several markets.

Improved earnings and clear priorities

We are combining our growth efforts with disciplined cost control. The gross margin improved to 65 percent (62), the operating result to SEK -3.9 million (-8.2) and cash flow from operating activities to SEK -5.8 million (-12.2). In addition, we have strengthened our financial position through a three-year loan agreement with Almi for SEK 10 million and have received loans of SEK 11 million from related parties.

We have also strengthened the organization for the next phase of our development. Production expertise has been given a more prominent role in the Group Management Team, while we have broadened our commercial leadership through the recruitment of Katja Margell as Director of Investor Relations & Corporate Affairs.

Our unique, scientifically proven product gives us a foundation for continued growth in Sweden and expansion into new markets. I look forward to what lies ahead with great confidence, and the entire organization is committed and ready to bring ColdZyme to more markets.

Sana Alajmovic, CEO



Enzymatica at a glance

Enzymatica develops innovative self-care products, based on its barrier technology platform. Enzymatica was founded in 2007, has its head office in Lund, Sweden, and has been listed on the Nasdaq First North Growth Market since 2015.

The main product is the ColdZyme mouth spray – a spray used at the first signs of a cold. ColdZyme is sold in Sweden, the United Kingdom and Iceland through the company's own contract organizations, while distribution in other markets takes place through partnership agreements with leading consumer healthcare companies. Developing additional international partnerships remains an important part of Enzymatica's growth strategy.

Research

Enzymatica's research is conducted in collaboration with leading universities and research groups. The company's products are evaluated both in independent research studies and in studies initiated by Enzymatica. The most recent independent studies, conducted by researchers at the University of Kent and the Medical University of Vienna, were published in *The Journal of Physiology* in February 2025.

The randomized, double-blind, placebo-controlled study represents an important part of Enzymatica's strategy for continued international expansion and the relaunch of ColdZyme in Europe. Together with the MDR certification that ColdZyme received in 2024, it reinforces the company's ability to establish the product in new markets.

In the United Kingdom, the clinical study also serves as important support for marketing ColdZyme, as independent

clinical documentation is required to communicate the product's claims directly to consumers.

Building on this clinical documentation, Enzymatica continues to refine the product's positioning, bolster its product claims within current regulatory requirements and identify the most effective commercial opportunities for continued international growth.

Seasonal variations

Sales of cold products are affected by seasonal variations. In Europe and other northern markets, the cold season usually begins in late autumn and subsides in March–April.

Financial targets

When the new CEO took office in early 2026, the Board of Directors began reviewing Enzymatica's financial targets. In light of this, the previously communicated EBIT target of at least approximately SEK 170 million by the end of 2027 is under review and will be updated. The company intends to present updated targets later.



Financial overview – July-September 2026

Sales and market

Consolidated net sales in the third quarter of 2026 came in at SEK 14.6 (15.0) million – a 2.9 % year-on-year decrease compared with the same period in 2025. Lower sales to pharmacies in Sweden weighed on net sales for the quarter compared with the third quarter of the previous year, while sales in the UK remained strong, increasing by 51% to SEK 1.7 million.

The cold remedy market at pharmacies in Sweden increased 6.7% in value for the quarter compared with the same quarter in 2025. In the same period, ColdZyme sales from pharmacies increased by 10.6% in value compared with 2025. ColdZyme’s share of the total cold remedy market in terms of value was 6.5%, compared with 6.2% for the same period year-on-year (Source: IQVIA).

Performance

Gross profit for the quarter totaled SEK 9.5 million, compared with SEK 9.2 million in the third quarter of the previous year, corresponding to a gross margin of 65% (62). Enzymatica has experienced variations in gross margins between individual quarters. As in the previous year, higher costs paid to the company’s manufacturing partner for our rights to use its packaging line affected the gross margin for the quarter.


Total operating expenses for the quarter amounted to SEK 13.3 (17.5) million. The decrease was mainly due to lower selling and administrative expenses.

The consolidated operating loss was SEK -3.9 (-8.2) million. Net financial income and expenses for the period amounted to SEK -0.1 (-0.0) million. Tax expense for the period was

SEK -0.0 (-0.2) million. Impairment charges totaled SEK 1.6 (1.4) million.

Research, development and other investments

Total consolidated research and development expenses were in line with the plan and amounted to SEK 2.7 (2.6) million for the third quarter. The Group's investments in property, plant and equipment and intangible assets for the quarter totaled SEK 0.0 (0.1) million, of which SEK 0 (0) million are intangible assets. No expenses for development projects were capitalized during the quarter (0).



Financial overview – January–September 2026

Sales

Consolidated net sales for the period January–September came in at SEK 33.2 (35.6) million – a 6.8% year-on-year decrease compared with the same period in 2025.

The cold remedy market at pharmacies in Sweden grew by 0.2% in value during the interim period compared with the same period in 2025. In the same period, ColdZyme sales from pharmacies increased by 4.9% in value compared with 2025. (Source: IQVIA)

Performance

The gross margin for the period January–September was 58% (62%). Higher costs paid to the company's manufacturing partner for our rights to use its packaging line affected the gross margin for the period.

Total operating expenses for the period January–September were SEK 49.3 (63.5) million. The lower costs were mainly attributable to lower selling and administrative expenses, as well as lower research and development expenses.

The consolidated operating loss was SEK -30.1 (-41.1) million. The result for the period was SEK -30.4 million (-40.9). Finance net totaled SEK -0.2 (-0.2) million. Tax expense for the period was SEK 0.5 (0.1) million. Impairment charges totaled SEK 5.4 (4.1) million.

Research, development and other investments

Total consolidated research and development expenses were in line with the plan and amounted to SEK 8.6 (11.7) million.

The Group's investments in property, plant and equipment and intangible assets for the period January–September totaled SEK 0.1 (0.2) million, of which SEK 0 (0) million relate to intangible assets. No expenses for development projects were capitalized during the period (0).

Funding and cash flow

The Group's available funds at the end of the period totaled SEK 16.3 (34.8) million, of which SEK 6.7 (33.3) million were in cash and cash equivalents and SEK 9.7 (1.5) million in unutilized credit facilities.

Net cash at the end of the period totaled SEK 6.7 (31.8) million. Cash flow from operating activities from January through September totaled SEK -24.3 (-41.4) million. Cash flow from operating activities for Q3 came in at SEK -5.8 (-12.2) million. Total cash flow for the period amounted to SEK -26.5 (-42.1) million.

Enzymatica entered into a loan agreement with Almi for SEK 10 million on October 20. The loan has a three-year term, carries a variable interest rate of 7.79% and requires no principal repayments during the first 12 months.

In October, Enzymatica drew down SEK 11 million under its loan facilities, bringing the total liquidity from these facilities and the SEK 10 million loan granted by Almi to SEK 21 million.

Parent company

The parent company is responsible for group management and all operational activities, with the exception of enzyme production and the part of research and development that take place within the subsidiary Enzymatica ehf.

The parent company's net sales for the period January–September 2026 totaled SEK 30.6 million (33.6). Loss before tax came in at SEK -33.4 (-41.2) million. The parent company's investments in property, plant & equipment and intangible assets from January through September totaled SEK 0 (0) million and cash flow was SEK -26.8 (-41.6) million. Please see the consolidated figures for more information.

Staff

The number of people employed by the Group, converted to full-time positions, was 17 (21) at the end of the period. The employees included 5 (8) men and 12 (13) women.



Other information

The Group

Enzymatica AB (publ) (corporate identity no. 556719-9244), with its head office in Lund, Sweden, is the parent company of the following subsidiaries: Enzymatica ehf (corporate identity no. 6406830589), with its head office in Reykjavik, Iceland, and Enzymatica Care AB (corporate identity no. 556701- 7495), with its head office in Lund, Sweden.

Accounting policies

This interim report has been prepared in compliance with IAS 34 Interim Financial Reporting. The consolidated financial statements have been prepared in compliance with International Financial Reporting Standards (IFRS) as adopted by the EU, the Swedish Annual Accounts Act and the Swedish Financial Reporting Board's recommendation RFR 1 Accounting for Groups. The parent company's annual report has been prepared in compliance with the Swedish Annual Accounts Act and the Swedish Financial Reporting Board's recommendation RFR 2 Accounting for Legal Entities. Disclosures in accordance with IAS 34. 16A are incorporated in the financial statements and their accompanying notes, as well as in other parts of this interim report.

The recognition and measurement policies applied in the 2025 Annual Report have been applied in this interim report as well. The amendments to IFRS standards that became effective in 2026 have not had a material impact on the Group's earnings or financial position. Apart from IFRS 18, which takes effect in 2027, no material impact on the Group's or the parent company's financial statements is expected from new or amended standards that have not yet entered into force. IFRS 18 will affect presentation and disclosures.

Segment reporting

Enzymatica's operations currently include only one operating segment: medical devices. Please see the consolidated income statement and balance sheet for the reporting on this operating segment.

Audit

This report was reviewed by the Company's auditors, see page 18.

Incentive programs

The 2024 Annual General Meeting resolved on the warrant-based incentive program 2024/2027, comprising a maximum of 2,700,000 warrants for employees and consultants. A total of 2,130,000 warrants have been allotted and subscribed for during 2024 and 2025. Each warrant entitles the holder to subscribe for one new share at an exercise price of SEK 11.97 during the period June 1–June 30, 2027. Upon full exercise, the maximum dilution effect amounts to approximately 0.87%.

An Extraordinary General Meeting held on August 22, 2025 resolved on the warrant-based incentive program 2025/2028, comprising a maximum of 2,000,000 warrants for employees and consultants. A total of 1,000,000 warrants have been allotted and subscribed for. Each warrant entitles the holder to subscribe for one new share at an exercise price of SEK 4.82 during the period October 1–December 31, 2028. Upon full exercise, the maximum dilution effect amounts to approximately 0.82%.

An Extraordinary General Meeting held on October 22, 2026 resolved on the warrant-based incentive program 2026/2029, comprising a maximum of 1,000,000 warrants for employees and consultants. A total of 1,000,000

warrants have been allotted and subscribed for. Each warrant entitles the holder to subscribe for one new share at a preliminary exercise price of SEK 3.30 during the period October 1–December 31, 2029. Upon full exercise, the maximum dilution effect amounts to approximately 0.4%.

Related-party transactions

On April 8, 2026, Enzymatica AB signed a loan facility totaling SEK 8 million with Chairman of the Board Bengt Baron (SEK 2 million) and Board members Mats Andersson (SEK 4 million) and Helene Willberg (SEK 2 million), through their companies. The loan facility runs for three years with 10% interest and a 2% commitment fee. The loan facility has been entered into on market terms.

On October 1, 2026, Enzymatica AB signed a loan facility totaling SEK 3 million with Chairman of the Board Bengt Baron (SEK 0.75 million) and Board members Mats Andersson (SEK 1.5 million) and Helene Willberg (SEK 0.75 million), through their companies. The loan facility runs for three years with 10% interest and a 2% commitment fee. The loan facility has been entered into on market terms.

Information about risks and uncertainties

Enzymatica's operations remain exposed to several operational, commercial and financial risks. These include the company's ability to secure access to capital, develop and maintain commercial partnerships, and manage production and the supply chain in line with its business development.

The company continuously works to ensure an appropriate capital structure and strong financial preparedness to enable the execution of its long-term strategy. If access to external financing were to deteriorate, or if capital could not



Other information

be raised on acceptable terms, this could affect the company's ability to carry out planned activities.

Enzymatica's continued expansion and future revenue growth depend to a significant extent on successful collaborations with commercial partners. The company is in ongoing discussions with both existing and new partners to strengthen its presence in additional markets. If these processes take longer than expected or do not generate the expected sales volumes, the company's revenue and liquidity could be adversely affected and its funding needs could increase. In addition, the company continues to control costs, prioritize its activities and evaluate financing options to ensure continued operations and implementation of its long-term strategy.

Production is based on a combination of in-house manufacturing and external manufacturing and supply partners. Disruptions in production, limited access to raw materials or other deviations in the supply chain may temporarily affect the Group's delivery capacity.

Other risks to which the business is exposed include currency-related risks as well as changes in laws, regulations and regulatory requirements. Apart from this, no material changes have occurred regarding the risks and uncertainties described in the 2025 Annual Report.

Upcoming financial information

Year-end report 2026	February 18, 2027
2026 Annual Report	April 13, 2027
Interim report, Jan–March 2027	April 28, 2027
Annual General Meeting	May 13, 2027
Interim report, Jan–Jun 2027	July 16, 2027
Interim report, Jan–Sep 2027	October 22, 2027

The interim reports and annual report are available at www.enzymatica.com.

Interim report signatures

Lund, October 29, 2026

Sana Alajmovic
CEO

For questions about this report, please contact:

Sana Alajmovic, CEO, Enzymatica AB
+46 723 89 33 96 | sana.alajmovic@enzymatica.com

Holger Lembrér, CFO, Enzymatica AB
0722-30 77 10 | holger.lembrier@enzymatica.com

Publication

This information is information that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8:30 a.m. CEST on Thursday, October 29, 2026.

This report is an English translation of the Swedish original. In the event of any discrepancies between the two versions, the Swedish version shall prevail.

Street address

Enzymatica AB (publ), corp. ID no. 556719-9244.

Mailing address: Ideon Science Park, 223 70 Lund, Sweden
Street address: Scheelevägen 19, Ideon, Lund, Sweden
Tel: +46 46-286 31 00 | info@enzymatica.se |
www.enzymatica.se

Enzymatica AB (publ) is listed on the Nasdaq First North Growth Market. The Company is traded under the ticker symbol ENZY and ISIN code SE0003943620. Certified Adviser is DNB Carnegie Investment Bank AB (publ), certifiedadviser@carnegie.se



Condensed consolidated statement of comprehensive income

All amounts in SEK thousand	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	Jan-Dec 2025
Operating income					
Net sales	14 566	15 007	33 153	35 569	53 903
Cost of goods sold	-5 027	-5 765	-13 926	-13 473	-20 778
Gross profit	9 538	9 242	19 227	22 096	33 126
Sales & Marketing expenses	-2 583	-4 189	-11 638	-20 101	-27 438
Administrative expenses	-8 082	-10 773	-29 041	-31 698	-42 236
Research and development costs	-2 662	-2 581	-8 628	-11 715	-15 659
Other operating income	449	232	853	972	1 296
Other operating costs	-557	-163	-877	-698	-457
Operating profit/loss	-3 895	-8 231	-30 105	-41 144	-51 367
Profit/loss from financial items					
Interest income and similar profit/loss items	534	84	1 101	676	759
Interest expenses and similar profit/loss items	-597	-84	-943	-458	-1 231
Profit/loss after financial items	-3 957	-8 232	-29 946	-40 927	-51 839
Tax expenses	-49	-171	-483	63	-51
Profit/loss for the period	-4 007	-8 403	-30 429	-40 864	-51 890
Other comprehensive income:					
Items that have been redirected or may be included in the profit/loss:					
Translation difference of subsidiaries	-312	-35	153	-215	-695
Total other comprehensive income, net of tax	-312	-35	153	-215	-695
Total comprehensive income for the period	-4 318	-8 438	-30 276	-41 079	-52 586
Share attributable to parent company shareholders	-4 318	-8 438	-30 276	-41 079	-52 586



Earnings per share

	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	Jan-Dec 2025
Earnings per share, SEK (basic and diluted)	-0,02	-0,03	-0,13	-0,17	-0,21
Equity per share, SEK	0,39	0,56	0,39	0,56	0,51
Equity-asset ratio, %	76%	91%	76%	91%	87%
Number of outstanding shares	242 735 108	242 735 108	242 735 108	242 735 108	242 735 108
Average number of outstanding shares (basic and diluted)	242 735 108	242 735 108	242 735 108	242 735 108	242 735 108

Key financial indicators

Earnings per share

Profit/loss for the period in relation to average weighted number of shares.

Equity per share

Equity in relation to number of shares at the end of the period.

Equity ratio

Equity in relation to total assets.

Net cash/Net debt

Cash and cash equivalents less interest-bearing current and non-current liabilities. A negative amount means net debt.



Quarterly overview

All amounts in SEK thousand	Q3 2026	Q2 2026	Q1 2026	Q4 2025	Q3 2025
Net sales	14 566	7 147	11 440	18 334	15 007
Gross profit/loss	9 538	3 239	6 449	11 029	9 242
Gross margin in %	65%	45%	56%	60%	62%
Operating costs	-13 326	-16 065	-19 917	-21 818	-17 543
Operating profit/loss	-3 895	-12 639	-13 571	-10 223	-8 231
Profit/loss for the period	-4 007	-12 968	-13 455	-11 027	-8 403
Cash flow	-6 435	-12 936	-7 099	125	-12 215



Condensed consolidated statement of financial position

All amounts in SEK thousand	2026-09-30	2025-09-30	2025-12-31	2024-12-31
Assets				
Intangible assets	62 685	64 684	64 181	66 192
Right-of-use assets	13 800	1 305	1 022	2 201
Tangible assets	8 029	10 393	9 343	12 198
Financial assets	1 963	2 655	2 407	2 637
Inventories	14 062	17 971	18 915	16 708
Trade receivables	10 849	13 502	9 997	12 090
Other receivables	5 366	5 649	2 979	7 985
Cash and cash equivalents	6 691	33 080	33 134	75 212
Total assets	123 445	149 237	141 978	195 224
Equity and liabilities				
Equity	93 897	135 680	124 173	176 369
Non-current lease liabilities	10 909	190	8	1 022
Current lease liabilities	2 891	1 115	1 015	1 179
Trade payables	6 998	2 768	8 750	9 812
Other liabilities	8 749	9 483	8 033	6 842
Total equity and liabilities	123 445	149 237	141 978	195 224



Condensed consolidated statement of changes in equity

All amounts in SEK thousand	2026-09-30	2025-09-30	2025-12-31	2024-12-31
Opening balance	124 173	176 369	176 369	76 609
New share issue	-	-	-	159 147
Issue expenses related to New share issue	-	-	-	-7 424
Effect of option program	-	390	390	115
Total comprehensive income for the period	-30 276	-41 079	-52 586	-52 077
Closing balance	93 897	135 680	124 173	176 369



Condensed consolidated statement of cash flows

All amounts in SEK thousand	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	Jan-Dec 2025
Operating profit/loss	-3 895	-8 231	-30 105	-41 144	-51 367
Adjustments for non-cash items	Note 1	1 828	1 426	5 427	4 438
Financial items	-63	0	158	218	-472
Cash flow from operating activities before changes in working capital	-2 129	-6 806	-24 519	-36 488	-45 608
Changes in working capital	-3 493	-5 373	453	-4 950	4 636
Cash flow from operating activities	-5 622	-12 179	-24 066	-41 439	-40 972
Acquisition/disposal of property, plant & equipment	-30	-143	-104	-171	-231
Cash flow from investing activities	-30	-143	-104	-171	-231
Issued warrants	-	390	-	390	390
Transaction costs attributable to new share issue	-	-	-	-	-
Change in bank/overdraft facilities/leasing	-784	-283	-2 301	-896	-1 179
Cash flow from financing activities	-784	107	-2 301	-506	-789
Total cash flow for the period	-6 435	-12 215	-26 471	-42 116	-41 991
Cash and cash equivalents at start of period	13 145	45 289	33 134	75 212	75 212
Translation difference cash and cash equivalents	-18	6	28	-15	-87
Cash and cash equivalents at end of period	6 691	33 080	6 691	33 080	33 134

Note 1: Primarily related to depreciation.



Parent company income statement

All amounts in SEK thousand	Jul-Sep 2026	Jul-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	Jan-Dec 2025
Operating income					
Net sales	13 662	14 114	30 632	33 633	51 265
Cost of goods sold	-7 392	-10 692	-23 209	-24 393	-35 682
Gross profit	6 270	3 422	7 423	9 240	15 583
Sales & Marketing expenses	-2 481	-3 985	-11 101	-18 894	-25 820
Administrative expenses	-5 806	-6 821	-18 594	-20 156	-26 349
Research and development costs	-2 717	-2 030	-11 361	-12 049	-16 369
Other operating income	448	111	786	373	79
Other operating costs	-557	-161	-877	-687	-123
Operating profit/loss	-4 842	-9 464	-33 724	-42 173	-52 999
Profit/loss from financial items					
Interest income and similar profit/loss items	154	321	508	1 354	1 642
Interest expenses and similar profit/loss items	-66	-63	-152	-396	-1 120
Profit/loss after financial items	-4 754	-9 206	-33 369	-41 214	-52 477
Tax expenses	-	-	-	-	-
Profit/loss for the period	-4 754	-9 206	-33 369	-41 214	-52 477



Parent company balance sheet

All amounts in SEK thousand	2026-09-30	2025-09-30	2025-12-31	2024-12-31
Assets				
Intangible assets	379	2 377	1 874	3 886
Tangible assets	51	43	38	31
Financial assets	7 452	7 452	7 452	7 452
Inventories	13 042	15 477	17 638	13 823
Trade receivables	10 349	13 114	9 793	11 365
Receivables from group companies	302	7 640	5 162	9 744
Other receivables	3 541	3 566	2 005	6 430
Cash and bank balances	5 524	32 338	30 490	73 987
Total assets	40 639	82 007	74 452	126 717
Equity and liabilities				
Equity	27 265	71 896	60 633	112 721
Liabilities to group companies	915	-	-	-
Trade payables	6 704	2 167	8 164	8 783
Other liabilities	5 756	7 943	5 654	5 213
Total equity and liabilities	40 639	82 007	74 452	126 717



Report on review of interim financial information

Enzymatica AB (publ), corp. ID no. 556719- 9244

To the Board of Directors for Enzymatica AB (publ)

Introduction

We have reviewed the summary interim financial information (interim report) for Enzymatica AB (publ), company reg. no. 556719-9244, for the period January 1, 2026 to September 30, 2026. The Board of Directors and the CEO are responsible for the preparation and presentation of this interim report in accordance with IAS 34 and the Annual Accounts Act. Our responsibility is to express a conclusion on this interim report based on our review.

The scope of the limited review

We conducted our review in accordance with the International Standard on Review Engagements ISRE 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity. A review consists of making inquiries, primarily of persons responsible for financial and accounting issues, and conducting an analytical review and other review procedures.

A review is substantially less in scope than an audit conducted in accordance with the International Standards on Auditing and other generally accepted auditing standards. The procedures performed in a limited review do not enable us to obtain a level of assurance that would make us aware of all significant matters that might be identified in an audit.

The conclusion based on a review therefore does not provide the same assurance as a conclusion expressed based on an audit.

Conclusion

Based on our review, nothing has come to our attention that gives us cause to believe that the interim report was not prepared, in all material respects, in accordance with IAS 34 and the Annual Accounts Act for the Group and in accordance with the Annual Accounts Act for the Parent Company.

Malmö October 29, 2026

Deloitte AB

Jeanette Roosberg

Authorized public accountant



